Synopsis
Synopsis
0
KDMF
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Baysilon
2. Macroplastique
3. Poly(dimethylsiloxane)
4. Polydimethylsiloxane
5. Rtv S-5392
6. Silastic
7. Siliconique
8. Silikon 1000
9. Simpa
1. 107-51-7
2. Trisiloxane, Octamethyl-
3. Poly(dimethylsiloxane)
4. 1,1,1,3,3,5,5,5-octamethyltrisiloxane
5. Dimeticone
6. Dimethyl-bis(trimethylsilyloxy)silane
7. Dimethicone 350
8. 63148-62-9
9. Pentamethyl(trimethylsilyloxy)disiloxane
10. Dimethylbis(trimethylsiloxy)silane
11. 9g1zw13r0g
12. Chebi:9147
13. Trisiloxane, 1,1,1,3,3,5,5,5-octamethyl-
14. Dimethylbis(trimethylsilyloxy)silane
15. Dimethicones
16. Poly(dimethylsiloxane), Hydroxy Terminated
17. Mfcd00084411
18. Mfcd00134211
19. Mfcd00148360
20. Ccris 3198
21. Poly(dimethylsiloxane), Trimethylsiloxy Terminated
22. Einecs 203-497-4
23. Dimeticonum
24. Unii-9g1zw13r0g
25. Dimeticona
26. Frd 20
27. Ctamethyltrisiloxane
28. Mfcd00008264
29. Pentamethyl(trimethylsiloxy)disiloxane
30. Octamethyl-trisiloxane
31. Pdms
32. Dimethicone Macromolecule
33. Volasil Dm-1
34. Silicon Oil For Oil Bath
35. Trisiloxane [inci]
36. Dm-fluid 1.0cs
37. Ec 203-497-4
38. Octamethyltrisiloxane, 98%
39. Dsstox_cid_20710
40. Dsstox_rid_79558
41. Dsstox_gsid_40710
42. Os 20 (siloxane)
43. Schembl23459
44. Siliconoil Pharma 100 Cst.
45. Dimethyl Polysiloxane, Bis(trimethylsilyl)-terminated
46. Dow Corning High-vacuum Grease
47. Chembl2142985
48. Dtxsid9040710
49. Chebi:31498
50. Cxqxsvuqtkdnfp-uhfffaoysa-
51. Kf 96a1
52. Octamethyltrisiloxane [mi]
53. Dimethylbis(trimethylsiloxy)siliane
54. Polydimethylsiloxane, 1000 Cst.
55. Alpha-(trimethylsilyl)-omega-methylpoly(oxy(dimethylsilylene))
56. [(ch3)3sio]2si(ch3)2
57. Tox21_301002
58. Co9816
59. Mfcd00165850
60. Silane, Dimethylbis(trimethylsiloxy)-
61. Akos015840180
62. Zinc169747808
63. Antifoam Compound For Anhydrous Systems
64. Fs-4459
65. Ncgc00164100-01
66. Ncgc00164100-02
67. Ncgc00254904-01
68. Cas-107-51-7
69. Db-040764
70. Ft-0631598
71. Ft-0696355
72. O0257
73. O9816
74. C07261
75. D91850
76. S12475
77. A801717
78. Xiameter(r) Pmx-200 Silicone Fluid 1 Cst
79. J-001906
80. Poly(dimethylsiloxane), Viscosity 1.0 Cst (25 C)
81. Q2013799
82. Xiameter(r) Pmx-200 Silicone Fluid 20 Cs
83. 2,2,4,4,6,6-hexamethyl-3,5-dioxa-2,4,6-trisilaheptane
84. Polydimethylsiloxane, 20,000 Cst. Trimethoxysilyl Terminated
85. Polydimethylsiloxane, Extreme Low Volatility, Viscosity 1000 Cst.
86. Intermediate Viscosity Polydimethylsiloxane Antifoam Emulsion, 20% Active, Viscosity 1500cst
87. Intermediate Viscosity Polydimethylsiloxane Antifoam Emulsion, 30% Active, Viscosity 1500cst
88. Polydimethylsiloxane, Trimethylsiloxy Terminated, Reduced Volatility, Viscosity 20 Cst.
89. 28349-86-2
90. Intermediate Viscosity Polydimethylsiloxane Antifoam Emulsion, 10% Active, Viscosity 1000-2000cst
91. Intermediate Viscosity Polydimethylsiloxane Antifoam Emulsion, 10% Active, Viscosity 800-2000cst
92. Intermediate Viscosity Polydimethylsiloxane Antifoam Emulsion, 20% Active, Viscosity 1000-2000cst
93. Intermediate Viscosity Polydimethylsiloxane Antifoam Emulsion, 30% Active, Viscosity 1000-2000cst
94. Polydimethylsiloxane, Trimethylsiloxy Terminated, Extreme Low Volatility, Viscosity 12.500 Cst.
Molecular Weight | 236.53 g/mol |
---|---|
Molecular Formula | C8H24O2Si3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 4 |
Exact Mass | 236.10840961 g/mol |
Monoisotopic Mass | 236.10840961 g/mol |
Topological Polar Surface Area | 18.5 Ų |
Heavy Atom Count | 13 |
Formal Charge | 0 |
Complexity | 149 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
P - Antiparasitic products, insecticides and repellents
P03 - Ectoparasiticides, incl. scabicides, insecticides and repellents
P03A - Ectoparasiticides, incl. scabicides
P03AX - Other ectoparasiticides, incl. scabicides
P03AX05 - Dimeticone
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
38
PharmaCompass offers a list of Dimethicone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dimethicone manufacturer or Dimethicone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dimethicone manufacturer or Dimethicone supplier.
PharmaCompass also assists you with knowing the Dimethicone API Price utilized in the formulation of products. Dimethicone API Price is not always fixed or binding as the Dimethicone Price is obtained through a variety of data sources. The Dimethicone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Tox21_301002 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tox21_301002, including repackagers and relabelers. The FDA regulates Tox21_301002 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tox21_301002 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Tox21_301002 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Tox21_301002 supplier is an individual or a company that provides Tox21_301002 active pharmaceutical ingredient (API) or Tox21_301002 finished formulations upon request. The Tox21_301002 suppliers may include Tox21_301002 API manufacturers, exporters, distributors and traders.
click here to find a list of Tox21_301002 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Tox21_301002 DMF (Drug Master File) is a document detailing the whole manufacturing process of Tox21_301002 active pharmaceutical ingredient (API) in detail. Different forms of Tox21_301002 DMFs exist exist since differing nations have different regulations, such as Tox21_301002 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Tox21_301002 DMF submitted to regulatory agencies in the US is known as a USDMF. Tox21_301002 USDMF includes data on Tox21_301002's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tox21_301002 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Tox21_301002 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Tox21_301002 Drug Master File in Japan (Tox21_301002 JDMF) empowers Tox21_301002 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Tox21_301002 JDMF during the approval evaluation for pharmaceutical products. At the time of Tox21_301002 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Tox21_301002 suppliers with JDMF on PharmaCompass.
A Tox21_301002 CEP of the European Pharmacopoeia monograph is often referred to as a Tox21_301002 Certificate of Suitability (COS). The purpose of a Tox21_301002 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Tox21_301002 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Tox21_301002 to their clients by showing that a Tox21_301002 CEP has been issued for it. The manufacturer submits a Tox21_301002 CEP (COS) as part of the market authorization procedure, and it takes on the role of a Tox21_301002 CEP holder for the record. Additionally, the data presented in the Tox21_301002 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Tox21_301002 DMF.
A Tox21_301002 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Tox21_301002 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Tox21_301002 suppliers with CEP (COS) on PharmaCompass.
A Tox21_301002 written confirmation (Tox21_301002 WC) is an official document issued by a regulatory agency to a Tox21_301002 manufacturer, verifying that the manufacturing facility of a Tox21_301002 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tox21_301002 APIs or Tox21_301002 finished pharmaceutical products to another nation, regulatory agencies frequently require a Tox21_301002 WC (written confirmation) as part of the regulatory process.
click here to find a list of Tox21_301002 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tox21_301002 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Tox21_301002 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Tox21_301002 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Tox21_301002 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tox21_301002 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Tox21_301002 suppliers with NDC on PharmaCompass.
Tox21_301002 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Tox21_301002 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tox21_301002 GMP manufacturer or Tox21_301002 GMP API supplier for your needs.
A Tox21_301002 CoA (Certificate of Analysis) is a formal document that attests to Tox21_301002's compliance with Tox21_301002 specifications and serves as a tool for batch-level quality control.
Tox21_301002 CoA mostly includes findings from lab analyses of a specific batch. For each Tox21_301002 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Tox21_301002 may be tested according to a variety of international standards, such as European Pharmacopoeia (Tox21_301002 EP), Tox21_301002 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tox21_301002 USP).